A 2-year study of lipid and lipoprotein changes in postmenopausal women with tibolone and estrogen-progestin

Obstetrics and Gynecology

Volumn 87, Issue 4, 1996, Pages 593-599

  Milner, Maire H ^a   Sinnott, Margaret M ^b   Cooke, Tommy M ^b   Kelly, Alan ^b   McGill, Tony ^b   Harrison, Robert F ^b  

^a ROTUNDA HOSPITAL   (Ireland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; ESTROGEN; GESTAGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PREMPAK; TIBOLONE; TRIACYLGLYCEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; ESTROGEN THERAPY; FEMALE; HORMONE ACTION; HUMAN; LIPOPROTEIN BLOOD LEVEL; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0029964603     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1016/0029-7844(95)00468-8     Document Type: Article

References (28)

1. DeAloysio D, Fabiani AG, Mauloni M, Bottiglioni F. Use of Org OD14 for the treatment of climacteric complaints. Maturitas 1987; 1:49S-65S.
2. Walker ID, Davidson JF, Richards A, Yates R, McEwan HP. The effect of the synthetic steroid Org OD14 on fibrinolysis and blood lipids in menopausal women. Thromb Haemost 1985;53:303-5.
3. Rymer J, Crook D, Sidhu M, Chapman M, Stevenson JC. Effects of tibolone on serum concentrations of Lp (a) in postmenopausal women. Acta Endocrinol 1993;128:259-62.
4. Kloosterboer HJ, Benedek-Jaszmann LJ, Kicovic PM. Long-term effects of Org OD14 on lipid metabolism in postmenopausal women. Maturitas 1990;12:37-42.
5. La Rosa J. Metabolic effects of estrogen and progestin. Fertil Steril 1994;62:140S-6S.
6. Scanu AM, Fless GM. Lipoprotein (a). Heterogeneity and biological relevance. J Clin Invest 1990;85:1709-15.
7. Bengtsson C, Bjorkelund C, Lapidus L, Lissner L. Association of serum lipid concentrations and obesity with mortality in women: 20-year follow-up of participants in a prospective population study in Gothenburg, Sweden. BMJ 1993;307:1385-8.
8. Whitcroft SI, Crook D, Marsh M, Ellerington MC, Whitehead MI, Stevenson JC. Long-term effects of oral and transdermal hormone replacement therapies on serum lipid and lipoprotein concentrations. Obstet Gynecol 1994;84:222-6.
9. Burstein M, Samaille J. Sur un dosage rapide du cholesterol lie aux a-et aux b-lipoproteins du serum. Clin Chim Acta 1960;5:609.
10. Friedewald WT, Levy RI, Frederickson DS. Estimation of the concentration of LDL cholesterol in plasma, without use of the centrifuge. Clin Chem 1972;18:499-502.
11. Multiple Risk Factor Intervention Trial Research Group. Multiple risk factor intervention trial: Risk factor changes and mortality results. JAMA 1982;248:1465-77.
12. Stevenson JC, Crook D, Godsland IF. Influence of age and menopause on serum lipids and lipoproteins in healthy women. Atherosclerosis 1993;98:83-90.
13. Jenner JL, Ordovas JM, Lamon-Fava S, et al. Effects of age, sex, and menopausal status on plasma lipoprotein (a) levels. Circulation 1993;87:1135-41.
14. Crook D, Cust MP, Gangar KF, et al. Comparison of transdermal and oral estrogen-progestin replacement therapy: Effects on serum lipids and lipoproteins. Am J Obstet Gynecol 1992;166:950-5.
15. Chetkowski RJ, Meldrum DR, Steingold KA, Randle D, Lu JK, Eggena P, et al. Biologic effects of transdermal estradiol. N Engl J Med 1986;314:1615-20.
16. Krauss RM, Perlmann JA, Ray R, Pettiti D. Effects of estrogen dose and smoking on lipid and lipoprotein levels in postmenopausal women. Am J Obstet Gynecol 1988;158:1606-11.
17. Miller VT, Muesing RA, La Rosa JC, Stoy DB, Phillips EA, Stillman RJ. Effects of conjugated equine oestrogen with and without three different progestogens on lipoproteins, HDL subfractions and apolipoprotein A-I. Obstet Gynecol 1991;77:235-40.
18. Miller NE. Associations of HDL subclasses and apolipoproteins with ischaemic heart disease and coronary atherosclerosis. Am Heart J 1987;113:589-97.
19. La Rosa J, Pickar JH, Wild RA, Walsh J, Hirvonen E, Menopause Writing Group. Metabolic impact of adding medroxyprogesterone acetate to conjugated estrogen therapy in postmenopausal women. Obstet Gynecol 1994;84:987-95.
20. Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA 1995;273:199-208.
21. Khokha R, Huff MW, Wolfe BM. Divergent effects of d-norgestrel on the metabolism of rat VLDL and LDL apolipoproteins. J Lipid Res 1986;27:699-705.
22. Fair of face and sick at heart (editorial). Lancet 1991;338:1366-7.
23. Kim CJ, Jang HC, Cho DH, Min YK. Effects of hormone replacement therapy on Lp (a) and lipids in postmenopausal women. Arterioscler Thromb 1994;14:275-81.
24. Farish E, Rolton H, Barnes JF, Hart DM. Lipoprotein (a) concentrations in postmenopausal women taking norethisterone. BMJ 1991:303:694-4.
25. Lobo RA, Notelovitz M, Bernstein L, Khan FY, Ross K, Paul WL. Lp (a) lipoprotein: Relationship to cardiovascular disease risk factors, exercise and estrogen. Am J Obstet Gynecol 1992;166:1182-90.
26. Crook D, Sidhu M, O'Donnell M, Stevenson JC. Lp (a) levels in women given danazol, an impeded androgen. Atherosclerosis 1992;92:41-7.
27. Bhatnagar D, Durrington PN. Does measurement of the apolipoproteins add to the clinical diagnosis and management of the dyslipidaemias? Curr Opin Lipidol 1993;4:299-304.
28. Ballantyne D. Long term effects of antihypertensives on blood lipids. J Hum Hypertens 1990;4:S35-S7.